 Patients must have no history of gross hemoptysis defined as bright red blood of a 12 teaspoon or more or coagulopathy. Patients with history of major tumor-related bleeding that is not controlled despite locoregional treatment or at high risk of recurrent tumor-related bleeding will be excluded. 